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Herbal or botanical remedies consumption by the public is on
the increase in the western world [1,2]. This demand is often rooted
in the belief that herbal products, being natural, are safe to take and
can contribute positively to the management of disease states. This
tendency of using natural products for managing illnesses is by no
means new to health care [2]. While the earlier demand for herbs has
been diminished due to the new advances in drug synthesis, a review
of current drugs revealed a high percentage of them (about 25%) still
had a botanical origin [3]. In response to the public’s demand for a
better recognition of the natural products in health care, the United
States Congress established in 1994 the Dietary Supplements Health
and Education Act, also known as DSHEA. According to DSHEA,
dietary supplements (DS) are “intended to supplement the diet” by
providing the consumer with specific nutrients including vitamins,
minerals, herbs, amino acids, and others [2,4]. As such, the intention
of DSHEA was not to use these products for the management of disease
state, but rather to use them as “supplements” to the regular diet. The
US Food and Drug Administration (FDA) is the Federal agency that
regulates DS products available on the US market, while the Federal
Trade Commission monitors the “truth-in-advertising” claims
for any misleading information in DS advertisements [4]. Unlike
prescription or over-the-counter medications, DS manufacturers
do not have to submit to the FDA any safety or efficacy data prior to
marketing. In fact, it is the FDA’s responsibility to monitor the safety
of DS while they are being consumed by the public [2,4]. The current
Federal regulations require the manufacturer of DS to formulate and
package them under cGMP-controlled (current Good Manufacturing
Practice) environment [4]. The label on DS products usually contain
information related to the “structure-function” relationship that
a product is intended to provide, however it cannot state that the
product is useful for treating a specific “medical” condition. For
example, it can be stated on the label that St. John’s Wort (Hypericum
perforatum) is useful as a “mood enhancer,” but the manufacturer
cannot claim the herb’s usefulness in treating clinical depression.
Additional information on the standardized product’s label lists the
component(s) to which the standardization was based upon. For
Hypericum perforatum products, these are standardized with respect
to hypericin which is one of the “active” constituents in St. John’s Wort.
Some of the major concerns in health care are drug interactions.
The use of DS along with medications can result in drug-herb
interactions. Clinical investigations have documented major drugherb interactions especially those seen with sedative, anti-diabetic,
and anti-coagulation medications [2]. Moreover, there is a lack of
communication existing between the patients and their clinicians
concerning DS use; only 1 out of 4 patients communicates with
their physicians about DS use [5]. In addition, most consumers get
the information about DS products from friends and relatives and
not from their health care providers [6]. This combination of factors
presents a real concern in our current health care system. Some of
the DS products can produce serious side/toxic effects on their own
[4], and some are found adulterated with pharmaceutical drugs,
a problem often encountered with imported Traditional Chinese
Medicine products [5,7].
Research in the area of botanical medicine has been inadequate
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in its quality and quantity. This is perhaps related to the limited
availability of funding from the government. The US government
makes some fund available to researchers through its agencies
such as the National Center for Complementary and Alternative
Medicine (NCCAM) (National Institutes of Health). In addition,
there is a broad “dis-interest” by the pharmaceutical industry to
devote more time and money for scientific investigations related to
DS products. Review articles in the area of botanical medicine often
cite the various shortfalls of research which include inadequate
sample size, unacceptable experimental design, and/or various host
of methodological issues [8]. To overcome this negativity which is
often associated with DS research, more utilization of randomized
placebo-controlled clinical trial (RCTs) along with the use of
acceptable state of art scientific methodologies would certainly usher
a new era of discoveries. With respect to RCTs, researchers must
provide detailed information describing the patient population (age,
gender, weight, disease state, etc.) along with a clear description of
the randomization method, which is chosen in the research. In
addition, researchers must report all adverse events and side effects
documented during the course of the study. One of the major flaws in
this area is the lack of information pertaining to the DS product being
investigated, as preparations of the same botanical can vary greatly in
their composition [2]. Researchers in this area must use well-defined
standardized DS products and provide characteristics that include
the product’s natural origin (scientific name and parts of the plant
being used), source (geographic region, manufacturer, etc.), dosage
form (tablet, fluidextract, cream, etc.), and composition (a detailed list
of components with their concentrations). It is known that various
components of the same plant can produce synergistic or opposing
pharmacologic effects on individuals when present together in the
same formulation [e.g., ginsenosides’ effect (from Panax ginseng) on
blood glucose level] [1]. And, knowledge of the composition assures
that the subjects are certain to receive the desired dose of the “active”
ingredient(s) under investigation. It is also desirable that the dietary
supplements industry takes initiatives for identifying the toxicity
and the teratogenicity of the various components existing in the DS
formulation.
In conclusion, herbal preparations are being used alone or in
combination with pharmaceutical preparations, oftentimes without
the knowledge of the clinicians. Most consumers get their information
on DS from friends and family members. Major research flaws are
often encountered in the DS literature which may be remedied by
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standardizing the herbal preparations being tested and using more
appropriate experimental designs.
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